<DOC>
	<DOCNO>NCT02784886</DOCNO>
	<brief_summary>The purpose study determine whether , high risk population ( placenta praevia previous caesarean prenatal suspicion morbidly adherent placenta ( MAP ) ) , concentration cell-free fetal DNA circulate maternal plasma significantly increase subgroup morbidly adherent placenta ( MAP ) case , order determine dosage cell-free fetal DNA circulate maternal plasma may useful biological tool detect MAP , alone addition imagery finding ( ultrasonography RMI ) .</brief_summary>
	<brief_title>Cell-free Fetal DNA Circulating Maternal Plasma Marker Morbidly Adherent Placenta</brief_title>
	<detailed_description>Background : Morbidly adherent placenta ( MAP ) life-threatening condition characterize placental villus abnormally adherent myometrium . Prenatal identification MAP essential anticipate risk plan optimal delivery condition woman associate maternal outcome improvement . Prenatal identification base Doppler ultrasound and/or MRI associate high rate false-positive false-negative finding responsible adverse effect . Some case report suggest concentration cell-free fetal DNA circulate maternal plasma significantly increase context morbidly adherent placenta ( MAP ) . Objective : The primary objective determine whether concentration cell-free fetal DNA circulate maternal plasma significantly increase woman morbidly adherent placenta ( MAP ) compare woman placenta praevia previous caesarean . Secondary objective determine whether cell-free fetal DNA circulate maternal plasma useful biological tool detect MAP , alone addition imagery finding ( ultrasonography RMI ) , high risk population ( placenta praevia previous caesarean prenatal suspicion MAP ) . Design : Prospective observational study pregnant woman placenta praevia previous cesaeran prenatal suspicion placenta accreta , conduct 5 center . Methods : We expect include 83 woman risk MAP two year , approximately 17 ( 20 % ) MAP . Main outcome measure : The primary outcome measure concentration cell-free fetal DNA circulate maternal plasma . Conclusion : This study first prospective study include woman risk placenta accreta investigate whether concentration cell-free fetal DNA circulate maternal plasma increase MAP woman whether useful biological marker detect prenatally MAP high risk population .</detailed_description>
	<mesh_term>Placenta Accreta</mesh_term>
	<criteria>Every woman : deliver one 5 maternity unit participate Populationbased prospective observational study pregnant woman placenta praevia previous cesarean prenatal suspicion accreta ( PACCRETA ) . With placenta praevia least one previous cesarean delivery prenatal suspicion placenta accreta age 18 Every woman : understanding French . refuse participate study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Placenta accreta</keyword>
	<keyword>previous caesarean</keyword>
	<keyword>placenta praevia</keyword>
	<keyword>Cell-free fetal DNA</keyword>
	<keyword>Biological marker</keyword>
</DOC>